<DOC>
	<DOCNO>NCT01685762</DOCNO>
	<brief_summary>The purpose study see metformin effective make endometrial hyperplasia without atypia well return tissue normal state .</brief_summary>
	<brief_title>Metformin Treatment Endometrial Hyperplasia</brief_title>
	<detailed_description>This multi-institutional pilot clinical trial design estimate response rate safety metformin treatment simple complex endometrial hyperplasia ( EH ) without atypia . Enrollment patient occur UNC-Chapel Hill Southern Pines Women 's Health Center . Fifteen patient enrol course 1 year . Metformin initiate 850 mg orally daily , titrate twice daily minimum 1 month time . Treatment last 12 week patient undergo repeat endometrial biopsy ass regression persistence EH .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Be age 1875 year old Have confirm diagnosis endometrial hyperplasia without atypia base upon endometrial biopsy Have contraindication shortterm metformin therapy Have creatinine clearance ≥ 90 ml/min , calculate CockroftGault formula Have normal serum transaminase value ( AST ALT ) Need able undergo metformin treatment duration 12 week prior repeat endometrial biopsy Are currently take metformin take metformin past 6 month history allergic reaction intolerance time metformin Have history liver renal dysfunction . Have random glucose ≤ 65 ≥ 200 Have recent history alcoholism . Former alcoholic abstain alcohol 5 year may enrol study . Have history vitamin B12 deficiency Are pregnant Are currently take insulin Are take drug may significantly interact influence metabolism metformin In opinion investigator , patient felt appropriate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Endometrial hyperplasia</keyword>
	<keyword>Uterus</keyword>
	<keyword>Pilot</keyword>
	<keyword>Metformin</keyword>
</DOC>